Marketing authorisation for a medicine Medical devices Application for general reimbursement Inspection of pharmaceutical companies Company authorisations and registrations DKMAnet Clinical trials of medicines Fees Product defects and withdrawals
Theme

Strategy for the DKMA

The Danish Medicines Agency has formulated a strategy for 2022-26. The strategy emphasizes a vision of leading the way in national and international cooperation, and in the dialogue with citizens and society. Read more.

Go to theme
Theme

Vaccines and medicines against COVID-19

Read about the current studies and development of vaccines and medicines for treatment of COVID-19, and how medicines can be approved much quicker in extraordinary situations, if patient safety is sufficiently assured.

Go to theme

News and notifications

PRAC assesses that NAION could be a very rare side effect of Ozempic, Rybelsus and Wegovy

19 March 2026

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) recommends that the product information for semaglutide medicines should include information that the rare eye condition NAION could be a very rare side effect. Treatment should be stopped if symptoms of NAION occur.

Electronic dispatch of decision letters marks its fifth anniversary

04 February 2026

Updating of summaries of product characteristics due to changed ATC codes for 2026

05 January 2026

Danish Medicines Agency strengthens its organisational foundation to prepare for tomorrow's tasks

11 November 2025